Brokerages Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Target Price at $18.75

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have earned a consensus recommendation of “Buy” from the nine research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $18.75.

Several analysts have recently weighed in on LXEO shares. Wall Street Zen downgraded shares of Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday. Chardan Capital upgraded shares of Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Finally, JPMorgan Chase & Co. lowered their price objective on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, June 25th.

Insider Activity at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 25,947 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total transaction of $116,242.56. Following the transaction, the chief executive officer owned 377,817 shares of the company’s stock, valued at $1,692,620.16. This represents a 6.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total value of $98,592.52. Following the completion of the transaction, the insider owned 82,194 shares of the company’s stock, valued at $363,297.48. The trade was a 21.35% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 57,560 shares of company stock valued at $256,577 over the last three months. Insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Lexeo Therapeutics

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in shares of Lexeo Therapeutics in the 2nd quarter valued at about $26,717,000. RA Capital Management L.P. acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at about $49,650,000. Paradigm Biocapital Advisors LP purchased a new stake in Lexeo Therapeutics during the fourth quarter worth about $47,299,000. Balyasny Asset Management L.P. purchased a new stake in Lexeo Therapeutics during the second quarter worth about $16,117,000. Finally, Jupiter Topco LLC acquired a new position in Lexeo Therapeutics during the second quarter worth about $18,409,000. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Price Performance

Shares of NASDAQ:LXEO opened at $4.84 on Monday. Lexeo Therapeutics has a fifty-two week low of $3.99 and a fifty-two week high of $10.99. The firm’s 50 day moving average price is $4.65 and its 200 day moving average price is $5.62. The stock has a market cap of $397.12 million, a price-to-earnings ratio of -4.21 and a beta of 1.46.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Wednesday, August 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). On average, equities analysts anticipate that Lexeo Therapeutics will post -1.2 EPS for the current year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.